NCT03991884
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +23 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Refractory B Lymphoblastic Lymphoma
Explore clinical trials studying Refractory B Lymphoblastic Lymphoma. Study availability and eligibility vary by location and protocol.
3 public trials
0 recruiting studies
Refractory B Lymphoblastic Lymphoma trial results
Active, Not Recruiting
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +23 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, Not Recruiting
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
NCT03504644
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
- Locations
-
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States